Sentences with phrase «ips cell research»

At least one biotech company (iPierian) has been founded to exploit the commercial potential of these reprogramming technologies, and the Japanese government has established an entire research institute dedicated to fundamental and applied iPSC research (Center for iPS Cell Research and Application, Kyoto University).

Dr. Yamanaka is also a Professor of Anatomy at the University of California, San Francisco, as well as the Director of the Center for iPS Cell Research and Application (CiRA) and a Principal Investigator at the Institute for Integrated Cell - Material Sciences, both at Kyoto University.

Ogawa - Yamanaka Prize committee members include George Daley, PhD (professor of hematology / oncology and director of the Stem Cell Transplantation Program at Boston's Children Hospital), Hideyuki Okano, MD, PhD (chairman of Keio University Graduate School of Medicine), Shinya Yamanaka, MD, PhD (senior investigator at the Gladstone Institutes and director of the Center for iPS Cell Research and Application, Kyoto University), Srivastava, and Wernig.

Researchers from the University of California, San Francisco (UCSF), University of Tsukuba, and the Center for iPS Cell Research and Application (CiRA) also took part in the research.

Prior to moving the study to a second patient, Dr. Takahashi chose to delay the trial as part of a safety validation step and in consideration of anticipated regulatory changes to iPS cell research in Japan.

Dr. Yamanaka, who did his postdoctoral training at Gladstone in the 1990s, also directs the Center for iPS Cell Research and Application (CiRA), and is a principal investigator at the Institute for Integrated Cell - Material Sciences (iCeMS)-- both located at Japan's Kyoto University.

Dr. Yamanaka is director of the Center for iPS Cell Research and Application (CiRA), Institute for Integrated Cell - Material Sciences (iCeMS), and professor at the Institute for Frontier Medical Sciences, Kyoto University.

Senior Investigator, Gladstone Institutes; Director of the Center for iPS Cell Research and Application, Kyoto University

5:00 - 6:00 pm — Shinya Yamanaka and Deepak Srivastava join a panel on ethical considerations for clinical translation of iPS cell research.

Without a safer technique, the promise of iPS cell research remained in the future.

Yamanaka, 55, is now director of the Center for iPS Cell Research and Application (CiRA) at Kyoto University, which conducted the genetic analysis for the first iPS cells to be transplanted into a human.

Both scientists continue their research at the Gladstone Institutes and at the Center for iPS Cell Research and Application in Kyoto, Japan.

With the new mRNA method for producing iPS cells the prospects for iPS cell research are better than ever.

In part, the Center builds on pioneering work done by Gladstone Senior Investigator Shinya Yamanaka, MD, PhD — who currently divides his time between Gladstone and Kyoto University's Center for iPS Cell Research and Application (CiRA).

For this study, five laboratories at the university's Center for iPS Cell Research and Application (CiRA) collaborated.

«These findings give a rationale to start autologous transplantation — at least of neural cells — in clinical situations,» says senior author Dr. Jun Takahashi, of the Kyoto University's Center for iPS Cell Research and Application.

«Dolly the Sheep told me that nuclear reprogramming is possible even in mammalian cells and encouraged me to start my own project, wrote Yamanaka, who splits his time between the University of California, San Francisco, and the Center for iPS Cell Research and Application (CiRA) at Kyoto University in Japan, which he directs.

The iPS cell research is not in question, but a frenzy of anonymous bloggers searching for flaws in prominent researchers» papers did find fault with one of his older publications.

«The kidney is a very solid organ, which makes it very difficult to bring enough number of cells upon transplantation,» explains Professor Kenji Osafune, whose lab at the Center for iPS Cell Research and Application (CiRA) at Kyoto University, Japan, is using iPSCs to investigate new treatments for kidney disease.

Materials provided by Center for iPS Cell Research and Application - Kyoto University.

In response to a query from Science, Kyoto University's Center for iPS Cell Research and Application, which Yamanaka directs, issued a statement that reads in part: «Our university filed the world's first patent application associated with iPS [cell] technology and is now trying to acquire patent rights in many countries, including the U.S..

Researchers at the Center for iPS Cell Research and Application (CiRA), Kyoto University, took advantage of this strategy by reprogramming FOP patient cells and then seeking candidate molecules that could explain how the disease initiates.

To capitalize on the discovery, Kyoto University set up the $ 40 - million Center for iPS Cell Research and Application (CiRA), which Yamanaka directs.

«For a long time now, the entire field was collecting data on MYC, LIN41, and other genes and proteins without knowing what most of it meant,» said Yamanaka, who is also director of the Center for iPS Cell Research and Application (CiRA) at Kyoto University, and professor at UC San Francisco.

Center for iPS Cell Research and Application (CiRA), Institute for Integrated Cell - Material Sciences, Kyoto University, Kyoto 606-8507, Japan.

Not exact matches

We reported on iPS cells in Cutting Edge of the Jan / Feb 2008 issue, concerning Prof. Ian Wilmut's volte - face in his attitude to cloning, after embracing iPS research.

In 2005, before a Congressional hearing in the U.S., Prof. George Q. Daley of Harvard spoke forcefully and influentially about the necessity for embryonic stem - cell research to go ahead, and dismissed suggestions that one could work instead with «induced pluripotent stem cells» («iPS», i.e. stem cells reprogrammed from some cells of a living adult).

«It would be really nice to derive and compare iPS cells and cells made using the Dolly technique from the same individual to see which were most normal,» says Robin Lovell - Badge of the National Institute for Medical Research in London.

Core Research for Evolutional Science and Technology and Yamanaka iPS Cell Project, Japan Science and Technology Agency, Kawaguchi 332-0012, Japan.

Future research should not only compare how embryonic stem cells, iPS cells and adult stem cells differentiate, but focus on what effects the niche in which these cells will reside, when transplanted, will have on their characteristics, including tendencies to mutate into cancer cells, notes cell and stem cell biologist Olga Genbacev at the University of California, San Francisco, (U.C.S.F.) School of Medicine.

In the present study conducted at IDOR in conjunction with UFRJ, the research team observed that ZIKV infects human - derived iPS neural cells, neurospheres and cerebral organoids causing cell death, malformations and reducing growth by 40 %.

For him, he continued, the trail of research that led to induced pluripotent stem (iPS) cells — the epochal advance that earned him the prize — began with his amazement at a photograph of a Drosophila (fruit fly) with a leg emerging from its eye.

They expressed concern that Japan «is in danger of being overtaken in the field of human iPS - cell research» because of government regulations.

Scientists anticipate that they'll be able to use iPS cells for much of the research they have been planning with human embryonic stem (ES) cells.

Shinya Yamanaka, MD, PhD, a UCSF professor of anatomy and a senior investigator with the UCSF - affiliated Gladstone Institutes, as well as the director of the Center for iPSCell Research and Application (CiRA) and a principal investigator at Kyoto University, shared the Nobel Prize in 2012 for discovering how to make iPS cells from skin cells using a handful of protein «factors.»

Kühn has just recently joined the MDC and is head of the research group for «iPS cell based disease modeling.»

The far - reaching potential of iPS research, combined with a higher likelihood that cell lines will stay linked to a single donor (and that donor's health history), heightens the need for consensus, said Timothy Caulfield, research director of the Health Law Institute at the University of Alberta in Edmonton.

That optimism, however, may be misplaced; these transformed cells, known as induced pluripotent stem cells (iPS cells), actually present equally troubling ethical quandaries, according to bioethicists who met at the International Society for Stem Cell Research annual meeting in June.

Donors might share in some monetary rewards and be able to opt out of certain uses for iPS cells, such as for creating gametes or mixed species, or have a say in the overall direction of research, Solbakk suggested.

We have now discovered that this factor also acts as a catalyst when reprogramming adult cells into iPS,» explains Thomas Graf, senior group leader at the CRG and ICREA research professor.

In the field of iPS cell - based regenerative medicine, advanced research with clinical applications for many organs and tissues, such as the retina, has steadily progressed.

The paper won't silence all doubts about iPS cells, says stem cell biologist Andras Nagy of the Lunenfeld - Tanenbaum Research Institute of Mount Sinai Hospital in Toronto, Canada.

The current research team, which includes Dr. Minoda and Dr. Hiroki Takeda of Kumamoto University, and several researchers from Keio University, have successfully grafted human iPS - derived cells into the inner ear of embryonic mice, a feat with a high level of technical difficulty.

First, the research team succeeded in efficiently inducing inner ear cells expressing inner ear specific proteins, such as CONNEXIN 26, CONNEXIN 30, and PENDRIN, from human iPS cells.

Center for Induced Pluripotent Stem (iPS) Cell Research and Application, Institute for Integrated Cell - Material Sciences, Kyoto University, Kyoto 606-8507, Japan.

The rise of these iPS cells has reduced the need for embryonic stem cells — which have long caused ethical concerns for some — and iPS cells now form the basis for most of today's stem cell research.

The team's current research project also involved directly converting skin cells into OPCs without having to create iPS cells.

The mice show many of the symptoms that human patients do, and so they were an especially good candidate to test iPS cells» abilities, says stem cell researcher Rudolf Jaenisch of the Whitehead Institute for Biomedical Research and the Massachusetts Institute of Technology, both in Cambridge, who collaborated with Townes on the project.

Regenerative medicine has made remarkable progress due to research with embryonic stem (ES) cells and induced pluripotent stem (iPS) cells.

The standard way to make induced pluripotent stem (iPS) cells for medical research is to scrape skin cells and mix up their internal clocks, coaxing them back into pluripotency over a matter of weeks.